Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Tiberi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancers|November 27, 2021
Molecular Targets and Emerging Therapies for Advanced Gallbladder CancerMatteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, et al.
Oncology and Therapy|May 26, 2025
Immunotherapy in Triple-Negative Breast CancerElisa Tiberi, Alessandro Parisi, Mirco Pistelli, et al.
Cancer Chemotherapy and Pharmacology|March 12, 2025
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literatureCarolina Liguori, Simona Magi, Alessandra Mandolesi, et al.
Therapeutic Advances in Medical Oncology|February 26, 2026
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancerAndrea Pretta, Riccardo Giampieri, Pina Ziranu, et al.
International Journal of Molecular Sciences|August 12, 2022
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical StudyLaura Lupini, Roberta Roncarati, Lorenzo Belluomini, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian studyRoberta Scafetta, Raffaella Troiano, Carla Gullotta, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancers|November 27, 2021
Molecular Targets and Emerging Therapies for Advanced Gallbladder CancerMatteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, et al.
Oncology and Therapy|May 26, 2025
Immunotherapy in Triple-Negative Breast CancerElisa Tiberi, Alessandro Parisi, Mirco Pistelli, et al.
Cancer Chemotherapy and Pharmacology|March 12, 2025
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literatureCarolina Liguori, Simona Magi, Alessandra Mandolesi, et al.
Therapeutic Advances in Medical Oncology|February 26, 2026
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancerAndrea Pretta, Riccardo Giampieri, Pina Ziranu, et al.
International Journal of Molecular Sciences|August 12, 2022
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical StudyLaura Lupini, Roberta Roncarati, Lorenzo Belluomini, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian studyRoberta Scafetta, Raffaella Troiano, Carla Gullotta, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 1